BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  FDA

  FDA Approves First Treatment for Severe Frostbite, Reduces Risk of Amputation

  Eicos Sciences’ injectable vasodilator Aurlumyn is the first FDA-approved medication for severe frostbite to reduce the risk of finger or toe amputation by opening blood vessels and preventing clotting.

  February 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Sage Touts Strong Launch for Postpartum Depression Drug Zurzuvae

  Despite missing out on an FDA approval for major depressive disorder, Zurzuvae appears to be a strong asset for Sage Therapeutics, with high growth potential in 2024.

  February 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Otsuka’s Longer-Acting Schizophrenia Injection to Offset Abilify Patent Loss

  A longer-acting formulation of Otsuka Pharmaceuticals’ aripiprazole could help soften the blow of Abilify Maintena’s loss of exclusivity coming later this year, according to a new report from GlobalData.

  February 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Roche-Backed Freenome Continues Industry’s Funding Rally with $254M Raise

  Freenome announced Thursday a fundraising round of more than a quarter of a billion dollars, led by Roche, to advance its blood-based cancer tests as pivotal readouts approach.

  February 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  ADC-Focused Firefly Bio Emerges from Stealth with $94M Series A

  Co-founded by Nobel Prize winner Carolyn Bertozzi, Firefly’s venture funding is backed by Eli Lilly and Versant Ventures, among others, to support its novel platform for merging antibody-drug conjugates with protein degraders.

  February 15, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Development

  Sanofi Gets Phase II MS Win, Eyes $5B in Peak Annual Sales for Pipeline

  The French drugmaker Thursday touted trial results in The New England Journal of Medicine showing frexalimab significantly slowed disease activity in people with relapsing multiple sclerosis.

  February 15, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Policy

  FDA Action Alert: Alvotech and Minerva

  In the next two weeks, the FDA is set to decide on a Humira biosimilar and a treatment for the negative symptoms of schizophrenia.

  February 15, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant

  CARBIOS and De Smet Engineers & Contractors jointly announce their collaboration to spearhead the construction of the world’s first PET biorecycling plant.

  February 15, 2024

   · 

  7 min read
• Business

  Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

  Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2023 and provided first full year 2024 sales and R&D expense guidance.

  February 15, 2024

   · 

  8 min read
• Senzime: Year-end Report January - December 2023

  Senzime AB Year-end report for January - December 2023 is now available on the company’s website.

  February 15, 2024

   · 

  3 min read